Nothing Special   »   [go: up one dir, main page]

DE60011462D1 - Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung - Google Patents

Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung

Info

Publication number
DE60011462D1
DE60011462D1 DE60011462T DE60011462T DE60011462D1 DE 60011462 D1 DE60011462 D1 DE 60011462D1 DE 60011462 T DE60011462 T DE 60011462T DE 60011462 T DE60011462 T DE 60011462T DE 60011462 D1 DE60011462 D1 DE 60011462D1
Authority
DE
Germany
Prior art keywords
group
calcimimetic
diamines
aralkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011462T
Other languages
English (en)
Inventor
Martial Ruat
Jean-Paul Potier
Robert Dodd
Marcel Dauban
Veronique Faure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE60011462D1 publication Critical patent/DE60011462D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60011462T 1999-11-09 2000-11-08 Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung Expired - Lifetime DE60011462D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9914050A FR2800735B1 (fr) 1999-11-09 1999-11-09 Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
PCT/FR2000/003104 WO2001034562A1 (fr) 1999-11-09 2000-11-08 Aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation

Publications (1)

Publication Number Publication Date
DE60011462D1 true DE60011462D1 (de) 2004-07-15

Family

ID=9551895

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60011462T Expired - Lifetime DE60011462D1 (de) 1999-11-09 2000-11-08 Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung

Country Status (8)

Country Link
EP (1) EP1235797B1 (de)
JP (1) JP2003513954A (de)
AT (1) ATE268752T1 (de)
AU (1) AU1400801A (de)
CA (1) CA2390880A1 (de)
DE (1) DE60011462D1 (de)
FR (1) FR2800735B1 (de)
WO (1) WO2001034562A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
GB2377635B (en) 2001-04-17 2005-10-19 Hoffmann La Roche Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
SI2821067T1 (en) 2003-09-12 2018-03-30 Amgen Inc. Quick spray formulation of cinacalcet
DK1757582T3 (en) 2004-05-28 2016-02-01 Mitsubishi Tanabe Pharma Corp Arylalkylamines AND MANUFACTURING METHOD THEREOF
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
EP1885693A4 (de) * 2005-05-18 2010-09-15 Siegfried Wurster Für die subtypen 1 und/oder 4 des somatostatinrezeptors selektive peptidomimetika
WO2007112280A1 (en) 2006-03-23 2007-10-04 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
EA200802166A1 (ru) 2006-04-20 2009-06-30 Эмджен Инк. Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
WO2008121386A2 (en) 2007-03-30 2008-10-09 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
EP2435404A1 (de) 2009-05-27 2012-04-04 Leo Pharma A/S Neue, calciumempfindliche rezeptoren modulierende verbindungen und deren pharmazeutische verwendung
JP2012528084A (ja) 2009-05-27 2012-11-12 レオ ファーマ アクティーゼルスカブ 新規のカルシウム感知受容体調節化合物およびその医薬用途
KR101706545B1 (ko) * 2010-03-04 2017-02-14 이에이 파마 가부시키가이샤 알킬아민 유도체
EP2588444A1 (de) 2010-06-30 2013-05-08 Leo Pharma A/S Neue polymorphe form einer calcimimetischen verbindung
JP5968880B2 (ja) 2010-06-30 2016-08-10 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
CN103391920A (zh) 2010-11-26 2013-11-13 利奥制药有限公司 钙敏感受体激活化合物
RU2013128968A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительного рецептора
CN103228619A (zh) * 2010-11-26 2013-07-31 利奥制药有限公司 钙传感受体活性化合物
RU2013128950A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Замещенные циклопентилазины в качестве casr-активных соединений

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2326004T3 (es) * 1996-05-01 2009-09-28 Nps Pharmaceuticals, Inc. Compuestos activos de receptor de ion inorganico.

Also Published As

Publication number Publication date
WO2001034562A1 (fr) 2001-05-17
CA2390880A1 (fr) 2001-05-17
EP1235797B1 (de) 2004-06-09
EP1235797A1 (de) 2002-09-04
FR2800735A1 (fr) 2001-05-11
ATE268752T1 (de) 2004-06-15
FR2800735B1 (fr) 2002-02-01
JP2003513954A (ja) 2003-04-15
AU1400801A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
DE60011462D1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
ATE557002T1 (de) Verbindungen mit calcimimetischer wirkung
ATE89263T1 (de) Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE52498T1 (de) Amidderivate.
DE3873612D1 (de) Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE71083T1 (de) L-dopa-derivate oder ihre saeureadditionssalze, verfahren zu ihrer herstellung und ihre verwendung.
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
ATE509910T1 (de) Vitamin d derivate mit einem 22-oxa- oder 22-thia-atom, einer sauer-, ester- oder amid- substitutierten c17-seitenkette und einer 16(17)- doppelbindung
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ATE143020T1 (de) Aminocarbonylcarbamate verwandt mit physostigmin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE206926T1 (de) Verwendung eines phosphorsäurediesters zur herstellung eines arzneimittels zur behandlung von akne
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ATE196080T1 (de) Verwendung von diphenylethanderivaten zur herstellung eines arzneimittels zur behandlung von glaukom
DE3765451D1 (de) 1(omega-(bis-(phenyl)-alkoxy)-alkyl)-4-(di-(phenyl)-methyl)- piperazine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
ATE69448T1 (de) Chinolincarbonsaeure-derivate, diese enthaltende zusammensetzung, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von medikamenten.
ATE130003T1 (de) Benzopyranderivate und verfahren zu deren herstellung.
ATE47839T1 (de) N-(2,6-disubstituierte aryl)-n'pyridinylharnstoffe, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen.
RU94033470A (ru) Циклогексановые производные, фармкомпозиция на их основе и способ лечения
DE69532963D1 (de) Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen
ATE187441T1 (de) 4-oxo-azetidin-2-sulfonsäureamide und ihre salze, verfahren zu deren herstellung und ihre verwendung
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
PT89483A (pt) Processo para a preparacao de derivados da 2-amino acetamida
ATE3295T1 (de) Clavulansaeure-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.

Legal Events

Date Code Title Description
8332 No legal effect for de